## R&D Portfolio June 2022 – 12 treatments delivered

### Screening
- **Leishmaniasis**
  - Hit-to-lead: NTD Drug Discovery Booster Hit-to-lead
  - 507 series: DNDI-4174
- **Chagas disease**
  - Screening: Hit-to-lead
  - UW series: Biomarkers
- **Filaria: River blindness**
  - NTD Drug Discovery Booster Hit-to-lead
  - CC4166
- **Mycetoma**
  - Screening: Pre-clinical profiling
- **HIV**
  - Nucleoside Booster: Broad-spectrum antiretroviral Hit-to-lead
  - TMEM16 series: Pre-clinical support
- **COVID-19 Pandemic Preparedness**
  - Nucleoside Booster: Moonshot
- **Malaria**

### Lead optimization
- **Leishmaniasis**
  - Hit-to-lead: NTD Drug Discovery Booster Hit-to-lead
- **Chagas disease**
  - Hit-to-lead: UW series
- **Filaria: River blindness**
  - NTD Drug Discovery Booster Hit-to-lead
- **Mycetoma**
  - Screening: Pre-clinical profiling
- **HIV**
  - Nucleoside Booster: TMEM16 series
- **COVID-19 Pandemic Preparedness**
  - Nucleoside Booster: Moonshot
- **Malaria**

### Pre-clinical
- **Leishmaniasis**
  - Hit-to-lead: 507 series
- **Chagas disease**
  - Hit-to-lead: UW series
- **Filaria: River blindness**
  - NTD Drug Discovery Booster Hit-to-lead
- **Mycetoma**
  - Screening: CC4166
- **HIV**
  - Nucleoside Booster: TMEM16 series
- **COVID-19 Pandemic Preparedness**
  - Nucleoside Booster: Moonshot
- **Malaria**

### Phase I
- **Leishmaniasis**
  - Hit-to-lead: DNDI-4174
  - NTD Drug Discovery Booster Hit-to-lead
- **Chagas disease**
  - Hit-to-lead: DNDI-4148
  - UW series: Biomarkers
- **Filaria: River blindness**
  - NTD Drug Discovery Booster Hit-to-lead
  - CC4166
  - Oxendazole
  - Emodepside
  - Flubendiloxin
- **Mycetoma**
  - Screening: Fosravuconazole
- **HIV**
  - Nucleoside Booster: TMEM16 series
  - Pre-clinical support
- **COVID-19 Pandemic Preparedness**
  - Nucleoside Booster: Moonshot
- **Malaria**

### Phase IIa/Proof-of-concept
- **Leishmaniasis**
  - Hit-to-lead: DNDI-4174
  - NTD Drug Discovery Booster Hit-to-lead
- **Chagas disease**
  - Hit-to-lead: DNDI-4148
  - UW series: Biomarkers
- **Filaria: River blindness**
  - NTD Drug Discovery Booster Hit-to-lead
  - CC4166
  - Oxendazole
  - Emodepside
  - Flubendiloxin
- **Mycetoma**
  - Screening: Fosravuconazole
- **HIV**
  - Nucleoside Booster: TMEM16 series
  - Pre-clinical support
- **COVID-19 Pandemic Preparedness**
  - Nucleoside Booster: Moonshot
- **Malaria**

### Phase IIb/III
- **Leishmaniasis**
  - Hit-to-lead: DNDI-4174
  - NTD Drug Discovery Booster Hit-to-lead
- **Chagas disease**
  - Hit-to-lead: DNDI-4148
  - UW series: Biomarkers
- **Filaria: River blindness**
  - NTD Drug Discovery Booster Hit-to-lead
  - CC4166
  - Oxendazole
  - Emodepside
  - Flubendiloxin
- **Mycetoma**
  - Screening: Fosravuconazole
- **HIV**
  - Nucleoside Booster: TMEM16 series
  - Pre-clinical support
- **COVID-19 Pandemic Preparedness**
  - Nucleoside Booster: Moonshot
- **Malaria**

### Development
- **Leishmaniasis**
  - Hit-to-lead: DNDI-4174
  - NTD Drug Discovery Booster Hit-to-lead
- **Chagas disease**
  - Hit-to-lead: DNDI-4148
  - UW series: Biomarkers
- **Filaria: River blindness**
  - NTD Drug Discovery Booster Hit-to-lead
  - CC4166
  - Oxendazole
  - Emodepside
  - Flubendiloxin
- **Mycetoma**
  - Screening: Fosravuconazole
- **HIV**
  - Nucleoside Booster: TMEM16 series
  - Pre-clinical support
- **COVID-19 Pandemic Preparedness**
  - Nucleoside Booster: Moonshot
- **Malaria**

### Implementation
- **Fexinidazole for T.b. gambiensis**
- **Fexinidazole for T.b. rhodesiense**
- **550&D (East Africa)**
- **New VL treatments (South Asia)**
- **New treatments for HIV/VI**
- **New VL treatments (Latin America)**

### Treatment access
- **Super-booster for children with HIV/TB**
- **4-in-1 (ABC/3TC/LPV/r)**
- **2-in-1 LPV/r pellets**
- **5 FC, LamB access (crypto meningitis)**
- **Ravidasvir + sofosbuvir**
- **Ravidasvir and other DAAs**
- **Fixed-dose combination ASM0**
- **Fixed-dose combination ASM0**

*Implementation transferred to the Medicines for Malaria Venture in 2015*  
*All NCE (New Chemical Entity)*  
*Treatments delivered by DNDi with partners*  
*Treatments not delivered by DNDi, but DNDi working on access*